DruSiLa: an integrated, in-silico disease similarity-based approach for drug repurposing
2022 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2022
; : 1879-1885, 2022.
Article
in English
| Scopus | ID: covidwho-2223060
ABSTRACT
The importance of faster drug development has never been more evident than in present time when the whole world is struggling to cope up with the COVID-19 pandemic. At times when timely development of effective drugs and treatment plans could potentially save millions of lives, drug repurposing is one area of medicine that has garnered much of research interest. Apart from experimental drug repurposing studies that happen within wet labs, lot many new quantitative methods have been proposed in the literature. In this paper, one such quantitative methods for drug repurposing is implemented and evaluated. DruSiLa (DRUg in-SIlico LAboratory) is an in-silico drug repurposing method that leverages disease similarity measures to quantitatively rank existing drugs for their potential therapeutic efficacy against novel diseases. The proposed method makes use of available, manually curated, and open datasets on diseases, their genetic origins, and disease-related patho-phenotypes. DruSiLa evaluates pairwise disease similarity scores of any given target disease to each known disease in our dataset. Such similarity scores are then propagated through disease-drug associations, and aggregated at drug nodes to rank them for their predicted effectiveness against the target disease. © 2022 IEEE.
Full text:
Available
Collection:
Databases of international organizations
Database:
Scopus
Language:
English
Journal:
2022 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2022
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS